Tivic Health Systems, Inc. (TIVC) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Tivic Health Systems year-end 2024 financial results and operational update conference call. This call has been pre-recorded and the questions you have submitted in advance will be answered following the prior remarks. This call is being webcast and the replay will be available on the IR section of the company website for three months. Before we begin, let me remind you that today's call management will make various forward-looking statements. Investors are cautioned that these forward-looking statements are based on current expectations and are subject to risk and uncertainties that could cause actual results or outcomes to differ materially from those indicated by our forward-looking statements. Please read the safe harbor statement contained in the press release we issued today, as well as those contained in typical health filings with the SEC, including its annual report on Form 10-K of the year end December 31st, 2024. to be filed with the SEC on or about March 21st, 2024, under the heading Risk Factors, as well as the company's other filings with the SEC. On today's call with Tivic Health's Chief Executive Officer, Jennifer Ernst, and Interim Chief Financial Officer, Lisa Wolf. Now, let me turn the call over to Jennifer. Thank you for that introduction. I am Jennifer Ernst, the CEO of Tivic Health, and welcome to our 2024 year-end corporate update. Now, while this is formally a look back at 2024, I have to say that much of what we did in 2024 has culminated in the last few weeks and considerably reshaped the company. We have advanced our vagus nerve stimulation program, and in February of 2025, we announced that we've acquired worldwide exclusive rights to a phase three immunomodulatory drug candidate. So I'd like to spend a portion of this, this fro...